1. Field of the Invention
The present invention relates to transgenic mouse models and, more particularly, to a transgenic mouse expressing human Pyrin-domain only (PYD) protein 2 (POP2).
2. Description of the Related Art
Inflammation is critical for clearing infections and responding to injury. However, excessive or prolonged inflammation contributes to irreversible tissue damage and the dysfunction of vital organs. Pro-inflammatory chemokines and cytokines, such as TNFα, IL-6, IL-8 and IL-1β, mediate inflammation. Most of these mediators are readily secreted as active form upon signal-induced synthesis, while the release of some other cytokines is tightly controlled. For example, the production of leaderless cytokines, such as IL-1 and IL-18, is controlled by several layers of enzymatic processes; (i) IL-1 or IL-18 is synthesized as a pro-form, which is cleaved by caspase-1 (a cysteine protease), (ii) the caspase-1, itself, is also synthesized as a pro-caspase-1, which is cleaved into active caspase-1 by inflammasome, and (iii) the inflammasome is a multi-protein complex structure formed by two or more proteins scattered in the cytoplasm, wherein they form a platform for self-cleaving of pro-caspase-1 into active caspase-1. Thus, the involvement of many steps in processing these cytokines highlights the importance of possible regulatory molecules that control unfettered activation and release of these cytokines as to avoid harmful effects in mammalian host.
Although the assembly of inflammasome structure is initiated by cytosolic sensors belonging to either the nod-like receptor (NLR) or the PYHIN family. NLR family proteins (e.g. NLRP3 and NLRC4) require an evolutionarily conserved Pyrin (PYD) or caspase recruitment domain (CARD), while members of the PYHIN family (e.g. AIM2) rely solely on a PYD. A homotypic PYD-PYD interaction between the sensor and apoptotic speck-like protein containing a CARD (ASC) is followed by recruitment of pro-caspase-1 via a CARD-CARD interaction.
Recently, viral and mammalian PYRIN domain-only proteins (POPs), comprised of essentially a solitary PYD, have been identified as likely regulators of inflammatory processes by inhibiting the NF-kB p65 signaling, limiting inflammasome formation, or both. Among mammalian species, POPs are evolutionarily recent, highly conserved, and appear to be restricted to higher primates, implying a unique role for these proteins in modulating the inflammatory responses. The recent identification and characterization of POP3 and an initial description of POP4 brings the number of human POP family members to four; all of which lack homologs in mice.
POP1 is expressed in human monocytes, macrophages and granulocytes, while POP2 in human testis, lymphocytes and macrophages. Moreover, knockdown of POP2 in human cells or stable expression in mouse cells has revealed the capacity of POP2 to limit the production of both TNFα and IL-1β. A recent study reported that POP3 is expressed in human monocyte and macrophages, but not B cells and T cells. POP4 exhibits a broad constitutive expression, but is induced in human macrophages. Functionally, POP1 inhibits IKKα and β, but it does not inhibit the NLRP3 inflammasome. However, POP2 impairs both NF-κB activation and NLRP3 inflammasomes; thereby limiting the production of both TNFα and IL-1β. Inhibition of NF-κB signaling by POP2 occurs at the level of NF-κB p65, likely through altering nuclear translocation of p65 and reducing the transactivation capacity of the RelA/p65 NF-κB transactivation domain 1. POP2 also reduces formation of NLRP3 inflammasomes by disrupting PYD-PYD interaction between ASC and NLRP3. The minimum peptide and specific residues of POP2 required for restricting both NF-kB activity and the NLRP3 inflammasome have been elucidated in in vitro cultured cells. Interestingly, POP3 has been shown to specifically inhibit the AIM2 inflammasome, but not that of NLRP3, while POP4 maintains a POP2-like NF-kB inhibitory capacity, but is likely not an inflammasome inhibitor.
Since mice lack the POP2 gene (as do all non-primate species), no knockout mouse model exists to elucidate the in vivo function of POP2. Thus, the exploration of POP2 function to date has been restricted to in vitro cellular models. Moreover, the creation of a mouse model using conventional approaches that results in overexpression of the relevant gene or a tissue expression pattern that is random will not be effective for replicating the expression of the gene in humans. Consequently, there is a need in the art for a mouse model that expresses POP2 in a manner consistent with the way the protein is expressed in humans and thus can be used to understand and evaluate the physiologic role of POP2 in humans.
The present invention comprises humanized mice expressing PYDC2 (POP2) represent an animal model for the regulation of inflammatory signaling by the primate-restricted POP2 protein. As POP2 is absent in small animal models used for human disease research, POP2 humanized mice represent a powerful tool for investigation of the function of POP2 in human health and disease, the impact of human drug treatments for inflammation-related conditions on the key regulatory pathways influenced by POP2, and a vehicle for testing therapeutics designed to enhance or restrict the action of POP2 to influence immunity. POP2 regulates late p65-mediated events in the NF-kB signaling pathway involved in inflammation, cell proliferation, cell survival, cellular differentiation, and cellular activation. POP2 also regulates the activation of the NLRP3 and AIM2 inflammasomes linked to a variety of human diseases including influenza, rheumatoid arthritis, Type II diabetes, gout, atherosclerotic heart and vascular disease, and septic shock. Further, the normal immune response to vaccines and infections also involve activation of the NLRP3 and/or AIM2 inflammasome as well as the NF-kB pathway. As POP2 regulates both of these inflammasomes together with the activation of NF-kB, humanized POP2 mice are a valuable resource for probing these connections.
The mice were been produced on the C57BL/6 genetic background (backcrossed for >9 generations) and extensively characterized for expression of POP2 in hematopoietic cells and tissues. Testing of the mice demonstrated that inflammatory processes controlled by POP2 are regulated in the mice (reduced cytokine production upon exposure to endotoxin and infection, including TNFalpha, IL-6, IL-1beta, IL-12, and others). Additionally, testing revealed data demonstrating that POP2 alters the outcome of inflammatory and infectious challenges to these mice.
The present invention will be more fully understood and appreciated by reading the following Detailed Description in conjunction with the accompanying drawings, in which:
Referring now to the drawings, wherein like reference numerals refer to like parts throughout, the present invention comprises the creation of a transgenic mouse model that would largely recapitulate the expression and function of human POP2. The model may be used to address the in vivo role of POP2 and to gain insight into its function in human health and disease. To better understand POP2 gene expression and achieve similar expression in a mouse, the “minimal” promoter elements required for POP2 transcription were identified. The POP2 promoter is likely contained within the 300 bp immediately upstream of the POP2 translation start site of the POP2 sequence (SEQ ID NO: 1). Such a short promoter is consistent with the observation that other newly emergent genes have short promoters. Nevertheless, 2000 bp upstream of the ATG (SEQ ID NO: 2) were used as an example of the present invention out of caution, and it should be recognized by those of skill in the art that there is always the possibility of distal enhancers or repressor sequences that are absent from the example of the invention yet involved in the regulation of POP2 expression.
For example, NLRP2, the “parent gene” of POP2, has a 5′ distal start site 4000 bp from its start codon, but the 5′ region of POP2 does not contain these NLRP2 sequences. Moreover, the emergence of POP2 is likely the result of a retrotransposition event, rather than one of classical gene duplication. While sequence analysis did not identify a transcription start site (TSS), suggesting POP2 may have a dispersed promoter recognized by RNA Pol II, a potential TFIIB binding site (TATA box) and two Inr elements that represent potential binding sites for TFIID were identified. The potential lack of a focused promoter is not surprising. Such promoters are more archaic, being found in early eukaryotes but less often in vertebrates, consistent with the late date (˜25 million years ago) and the primate-specificity of POP2. In contrast, the POP2 promoter does contains a TATA box, commonly associated with more primordial species and focused promoters. Experimental data demonstrates that very little of the POP2 5′UTR (127 nt) is required for NF-κB mediated expression. Searches based on the IκBα promoter NF-κB p65 binding sites, revealed two putative NF-κB p65 binding sites in the POP2 5′UTR located at −24 (NF-κB 1) and −36 bp (NF-κB 2) upstream of the ATG start codon. Preliminary results suggest that both may be involved (data not shown). The TATA box is important and likely required for NF-κB/p65-mediated POP2 transcription as the transcription activation domain 1 (TAD1) of NF-kB/p65 is known to associate with the TATA-box binding proteins TFIIB and TBP. Further, glucocorticoids silence NF-κB transcription of proinflammatory genes by disrupting p65 association with basal transcription machinery at the TATA box, suggesting that POP2 transcription may be sensitive to glucocorticoids. Since glucocorticoids are used for treatment of inflammatory conditions, an impact on POP2 might be reflected by an increase in POP2-sensitive inflammatory processes during glucocorticoid use. Indeed, the role of NF-kB and inflammatory cytokines in acquired glucocorticoid resistance is appreciated, but incompletely understood. While additional studies may help determine the role of the DNA sequence sites mediating transcription of POP2, the minimal promoter elements necessary to induce NF-κB mediated POP2 transcription are present in the present invention.
As described below, POP2 mRNA is increased as early as 10 min following LPS or TNF-α stimulation of THP-1 or primary macrophages suggesting rapid stabilization of otherwise unstable POP2 message. Indeed, an initial examination of mRNA decay and half-life confirms that POP2 mRNA has a short half-life, similar to that of TNFα, as more than 50% of its message was degraded by 30 min post-LPS stimulation in THP-1 cells. Mechanistically, a 3′ ARE element plays a role in this degradation. However, while the Wt ARE sequence is highly destabilizing, mutation of this element only partially restores POP2 expression, suggesting another stability regulating mechanism beyond the ARE. Rapidly induced NF-κB-dependent genes frequently contain multiple AREs in their 3′UTR mediating their rapid turnover. However, only one other potential ARE with a near-consensus sequence exists in the POP2 3′UTR (5′-ATTTTG-3′) which may or may not serve to destabilize POP2 message. A non-consensus A-U rich region in POP2 could also modulate stability of the mRNA as A-U rich message destabilizing sequences lacking a consensus ARE have been described. Further, RNA binding proteins with either stabilizing or destabilizing function possessing varied affinities for particular ARE sequences may participate. Nevertheless, the entire POP2 3′UTR (SEQ ID. NO. 3) through the poly-A signal (SEQ ID NO: 4), and thus whatever other regulatory sequences contributing to POP2 stability/decay, was used in the POP2 transgene construct of the present invention as it is likely contribute to regulated expression in POP2 transgenic mice. The minimal promoter region necessary for POP2 expression was located and used, including sites needed for NF-κB-mediated transcription, and a likely important ARE-mediated function of its 3′UTR was identified.
Prior to generating transgenic mice, J744 mouse macrophages were first reconstituted with the POP2 transgene (SEQ ID. NO: 5) to validate expression and function of POP2 in cells originating from a mouse. Transfectants constitutively expressing POP2 produce less TNFα and IL-1β upon exposure to TLR ligands and following bacterial infection. Further, we have yet to observe a difference in POP2 function between mouse and human macrophages in our structure/function analysis. Likewise, stable POP2 transgene transfectants of J774 cells, although exhibiting minimal to absent expression of POP2 without stimulation, exhibit markedly reduced production of various NF-kB-dependent cytokines and reduced processing of IL-1β. Having confirmed induction of POP2 gene expression and function in a mouse macrophage cell line, transgenic mice were generated using the POP2 transgene to begin elucidating the physiologic role of POP2 in various inflammatory conditions.
POP2 mice are physically indistinguishable from LMC mice. Gross and microscopic anatomic analyses of tissues revealed no difference in structural organization or size of any organs between POP2 and LMC mice suggesting that the POP2 transgene has no obvious impact upon developmental processes. Largely consistent with the expression of POP2 in human testis and at low levels in hematopoietic cells, POP2 mRNA was expressed constitutively in the spleen, lymph nodes, and testis of POP2Tg mice with little to no message detected in other tissues. The lack of splenic expression in human samples is intriguing, but may simply reflect a rapid loss of POP2 message due to time constraints during isolation of this organ. Immunophenotyping of immune cells from various compartments by multi-color flow cytometric analysis revealed no obvious differences between basic populations of thymocytes, single positive T cells, B cells, NK cells, macrophage and neutrophils from POP2 and LMC mice, with the exception of increased numbers of splenic neutrophils. This increase could result from extramedullary myelopoiesis in the spleens of POP2 mice. Although it remains possible that POP2 might prevent splenic neutrophil death or in some way favor neutrophil development, it is unclear why such an effect would not be evident in blood or lymph nodes. Curiously, an increase in neutrophils was also noted in the peritoneum, but this difference was not statistically significant. Nevertheless, myeloid cells, T cells, and B cells all constitutively express POP2 which accounts for its expression in secondary lymphoid tissues. The lack of obvious developmental impacts, especially in the hematopoietic compartment is interesting and largely suggests that expression of POP2, at least at the mRNA level, is not detrimental in any way.
POP2Tg mice are relatively resistant to LPS-induced septic shock or bacteria-induced septicemic death, possibly due to reduced production of proinflammatory cytokines. Consistently, POP2Tg mice had reduced serum levels of IL-1β, IL-6, IL-12, IL-18, TNFα and MCP-1; all of them are NF-kB dependent transcriptional targets, demonstrating that POP2 elicits an inhibitory or negative regulatory effect on NF-κB pathway during inflammatory process. Additionally, POP2 mice were protected against acute bacterial infections with a delay in mean time to death and greater survival than LMC mice following F. novicida or F. tularensis LVS infection. This suggests that POP2 has regulatory effect on inflammatory process, specifically during the early period of acute infection. Although the kinetics of this regulatory effect is unknown, but it might be overcome or sustained at later time in the course of infection. Further, in humans, the impact of POP2 on inflammatory process could be coordinated with other POP proteins, including POP1, POP3, and POP4, as well as CARD-only proteins (COP1, INCA, and ICEBERG). As most of these genes are also absent in mouse and most non-primate species, additional single and multiple transgenic mouse models will be needed. Nevertheless, delaying the onset of inflammatory processes and excessive inflammation may be beneficial in providing a window of opportunity for the host to mount adaptive responses while avoiding or limiting damage to the host tissues.
The resistance of POP2Tg mice to LPS injection supports the observed capacity of POP2 to limit activation of human NLRP3 and mouse Nlrp3 inflammasomes and is consistent with the resistant phenotype of Nlrp3−/− mice against LPS shock. Moreover, in vitro activation of the Nlrp3 inflammasome was blunted in POP2Tg mouse macrophages obtained from bone marrow, spleen, or peritoneum. The results demonstrate that POP2 inhibits both the human AIM2 and mouse Aim2 inflammasomes as seen by the diminished response of POP2Tg macrophages to the dsDNA analog and Aim2 ligand poly(dA:dT). Interestingly, POP1 has not been described to limit the activation of any inflammasome and POP4 lacks key residues required for NLRP3 inflammasome inhibition, but POP3 inhibits the AIM2 inflammasome. With the addition of AIM2 as a verified target of POP2, it appears that POP2 acts more broadly than the other POPs.
Quantitatively, there was a significant reduction in ASC-containing specks in POP2Tg cells suggesting that POP2 reduce ASC speck formation. Interestingly, multiple ASC-specks per cell were observed in wild-type cells, which was unusual as most often ASC-specks appear as a large, single, perinuclear aggregate. Indeed, in HeLa cells, ASC association is very rapid upon cellular stimulation and that it is an energy favorable reaction, makes it very unlikely that more than one speck would form in a cell. Potentially, the multiple specks were aggregates that were “moving” towards each other and would formed one large peri-nuclear speck had more time elapsed. This possibility seems unlikely though, as these were overnight infections, thus allowing plenty of time for complete, single speck formation that has been observed in THP-1 cells infected similarly. However, there exists a splice variant of ASC, detected in THP-1 cells among others, which lacks the proline and glycine-rich (PGR) domain between the PYD and CARD domain, but can still process IL-1β. It has been demonstrated that this splice variant of ASC, produces branched and diffuse ASC specks. Thus, potentially, a certain level of POP2 expression prevents splicing of the smaller ASC that could be inducing the multiple pecks observed in wild-type cells.
The presence of POP2Tg prevents cell death in macrophages infected with Fn or Ft LVS, as it inhibits Asc/Aim2- and Asc/Nlrp3-inflammsome formation. This suggests that POP2 might prevent both caspase-dependent and independent cell death in macrophages, which could serve as a pro-survival factor in mice. Supporting this, massive necrosis and macrophage cell death in lungs has been implicated in acute death of Ft LVS-infected mice. Contrastingly, a dichotomous pattern has been reported in relation to macrophage cell death and survival of mice between Wt and Asc KO or Casp-1 KO mice. A similar dichotomy exists for susceptibility/resistance patterns to Anthrax lethal toxin versus spores. However, the results with POP2 mice indicate that the overall nature of the inflammatory response is more important for clinical outcome of the disease than the immediate fate of macrophages, although this remains to be investigated.
The findings collectively demonstrate that human POP2 under the control of its endogenous regulatory elements exhibits expression patterns and functions in mice that are expected and consistent with our current understanding of POP2 from studies with human tissues and cells. NF-κB dependent cytokine production is restricted, the activation of both NLRP3 and AIM2-dependent inflammasome assembly is diminished with tempered IL-1β release, and inflammasome associated macrophage cell death is reduced. That POP2Tg mice exhibit greater resistance to LPS-induced shock and certain bacterial infections supports our hypothesis that humans possess POPs, and related COP proteins, to provide higher-order regulation of inflammation to limit inflammation-associated damage. In this circumstance, the role of POP2 is highly appreciated as the results of this study underscore a fundamental and inherent difference between higher-order primates and rodents in susceptibility to certain microbial pathogens. For example, Fn and Ft LVS are highly pathogenic to mice, but non-pathogenic to humans. However, when POP2 gene was introduced into the mouse, the transgenic mice (‘humanized’) show a resistance to infection by Fn and Ft LVS suggesting that POP2 gene play a vital role in primates by modulating host immune responses and thereby susceptibility to microbial infections. However, the effect of POP2 in modulating immune responses in other microbial infections needs to be studied.
Human POP2 is a small (97 aa) protein encoded by a primate-restricted single exon gene on chromosome 3. Because POP2 inhibits NF-kB and NLRP3 inflammasome activity and reduces TNFα and IL-1β production by macrophages, functionally POP2 is thought to regulate inflammatory processes in vivo. Although POP2 expression is increased several fold in THP-1 cells and primary human monocytes treated with LPS, PMA or TNFα, the genetic element that controls POP2 expression is unknown. As these stimuli mimick the inflammatory environment and strongly induce NF-κB activation, it is presumed that POP2 expression might be regulated by NF-κB. To test this theory, the POP2 genomic locus upstream of the ATG start codon was analyzed and, as a result, two NF-κB consensus binding sequences and a putative TATA box element was identified at −24, −36, and −82 nt upstream of the POP2 ATG start codon, respectively, as seen in
To identify the NF-κB responsive region, 5′ truncations were made in the POP2-Luc (-2000) construct including (-505), (-250) and (-127). Interestingly, luciferase activity from all the constructs was comparable in presence of p65, as seen in
Preliminary evaluation of POP2 expression in THP-1 and primary monocytes revealed the rapid induction (within 10 minutes) of POP2 mRNA by LPS and suggest likely post-trancriptional regulation of mRNA stability. To confirm this hypothesis, THP1 or U937 cells were treated with cyclohexamide (CHX) to prevent translation of proteins responsible for mRNA degradation. In these cells, POP2 mRNA expression was increased by 5 min following CHX treatment and did not decrease throughout the assay, as seen in
Genetic Reconstitution of Human POP2 in Murine Macrophages Recapitulates its Function
Prior to generating a POP2 transgenic mouse, genetic reconstitution of mouse macrophages with a human POP2 transgene was performed to determine whether it would recapitulate its expression and function. From the newfound knowledge of the regulation of POP2 gene expression, a POP2 transgene (POP2Tg) containing 2000 bp of upstream sequence was generated (which encompasses the NF-κB responsive and likely complete promoter), the single exon coding sequence, and the stability regulating 3′ UTR, as seen in
To assess the regulatory function of POP2 in J774A.1 macrophages, POP2Tg clones were treated with LPS or infected with Francisella novicida (Fn). It was found that these cells produced less IL-1β and TNFα, as seen in
Generation of Human POP2 Transgenic Mice
To study the regulatory role of POP2 in vivo, specifically on NF-kB and inflammasome pathways, POP2Tg mice expressing human POP2 were generated using the transgene construct described above. Two founders of POP2Tg mice (a male and a female) were generated on the C57BL/6×Balb/c background and the male founder successfully transmitted the POP2 transgene in the initial backcross to C57BL/6. Both POP2Tg and littermate control (LMC) pubs showed no birth defects or difference in general phenotypes and pre- and post-weaning behaviors. Both male and female POP2Tg mice are fertile and there are no apparent differences in age of sexual maturity. Litter size, body weight, weight of major organs, and sex distribution within litters and among POP2Tg and LMC mice were also unaffected, as seen in
To compare the expression pattern of POP2 in mouse tissues to previously published human data, mRNA analysis was performed for POP2 using perfused organs from POP2Tg and LMC mice. Initial RT-PCR analysis revealed POP2 expression in mouse testes, thymus, spleen, peripheral lymph nodes (pLN), heart, liver, kidney and lung, as seen in
Immunophenotyping of POP2 Mice
Since NF-κB is important for cell growth, development, and differentiation as well as controlling expression of various cytokine genes, and because POP2 is a demonstrated negative regulator of NF-κB, such regulation could influence normal development of immune cells in POP2Tg mice. As such, immune cells in spleen, pLN, thymus, blood, peritoneal fluid and bone marrow were immunophenotyped. Within the lymphoid compartment, CD4+ or CD8+ T cells (CD3+ subset), B cells (CD3-subset) and NK1.1 cells were identified, as seen in
POP2 Moderates the Cytokine Production in Macrophages by Inhibiting Nlrp3 and Aim2 Inflammasomes and NF-kB Pathway
In human monocytes/macrophages, POP2 inhibits NF-kB and inflammasomes. To confirm whether POP2 moderates the level of pro-inflammatory cytokines in transgenic mice, we harvested macrophages from bone marrow (BMDM), peritoneum or spleens of POP2Tg and LMC mice and treated with LPS plus Nlrp3 (ATP and nigericin) or Aim2 (poly(dA:dT) inflammasome activtors. POP2Tg BMDM produced significantly (p<0.05) less IL-1β IL-18, IL-6 and TNFα than that of LMC mice, as seen in
POP2 Mice Exhibit Resistance to LPS-Induced Endotoxemic Shock
Since POP2 inhibits NF-κB and inflammasomes in vitro, it was hypothesized that the normal physiologic role of POP2 is to limit excessive or uncontrolled inflammatory responses in vivo. To explore such a role, lethal septic shock was induced in POP2Tg and LMC mice by intraperitoneal injection of lethal dose of LPS (50 mg/kg). LMC mice were found to be 100% susceptible to lethal dose of LPS at 48 hours post-injection, while POP2Tg mice displayed a significant (p<0.05) delay in time to death with 20% of the mice surviving, as seen in
POP2Tg Mice are Less Susceptible to Acute Bacterial Infections
POP2 inhibits NF-kB and inflammasomes in macrophages and POP2 mice are resistant to LPS-induced endotoxemia through reduced serum TNFα, IL-6, IL-1β and IL-18 levels, consistent with previous studies demonstrating that elevated pro-inflammatory cytokines in response to TLR-mediated NF-kB signaling leads to endotoximic death. As such, it was hypothesized that inhibition of NF-kB or inflammasomes by POP2 might be detrimental during in vivo bacterial infections. To test this, the gram-negative bacterium Fn was used. Fn activates a NF-kB-mediated cytokine storm resulting in septicemic death of mice. Mice are highly susceptible to Fn, which primarily activates Aim2 inflammasome and survival requires an Aim2, ASC, and Caspase-1-dependent inflammasome response and IL-1β production. POP2 and LMC mice were subcutaneously infected with Fn (1.5×105 cfu) as described previously. Clinical signs of infection appeared early in LMC mice with 50% dying before day 5 and 70% by day 8 post-infection, as seen in
To confirm the protection against Ft LVS in POP2Tg mice, the bacterial burden in lungs was examined, as seen in
That Ft LVS infected POP2Tg mice were better protected than those infected with F. novicida lead to consideration whether the response of POP2Tg macrophages to these two bacterial strains might differ. While F. novicida infection of BMDM elicits a stronger IL-1β and IL-18 responses and a lower TNFα response than that seen with Ft LVS, the presence of POP2 similarly reduces both cytokines irrespective of the bacterial strain. However, the level of IL-6 was not different between POP2 and LMC mice. Thus, although it is possible that higher IL-1β production by infected macrophages in vivo might account for the relative inability of POP2 to protect mice against F. novicida infection, it is more plausible that other differences very likely contribute. For instance, survival of mice infected with F. novicida correlates positively with pyroptotic macrophage cell death mediated by the Aim2-Asc-Caspase-1 axis. Thus, macrophage death following infection with Ft LVS and F. novicida was compared. As expected, macrophages from POP2 mice exhibited less cell death than control macrophages at 24 hours post-infection. Although macrophage survival was expected to presage greater host susceptibility to infection, the opposite was observed. While POP2Tg macrophages are less susceptible to infection-mediated death, POP2Tg mice survive at least as well, if not better, than controls. The presence of POP2 thus seems to abrogate the correlation between the in vitro macrophage response and the in vivo response of the mouse, suggesting that in POP2 mice the nature of the macrophage response likely differs during in vivo infection.
Collectively, these observations demonstrate that while limiting the detrimental inflammatory responses contributing to septic shock, POP2 does not generally decrease resistance to bacterial infection. These features are consistent with the expected role of a bona fide inflammatory regulator and establish the hypothesis that POP2 beneficially regulates otherwise harmful inflammation. Further, POP2-mediated control of inflammatory responses during infection may favor protective responses by redirecting the cytokine and anti-bacterial activities of recruited inflammatory macrophages.
POP2Tg mice according to the present invention could be used for studies of the role of POP2 in human health and disease, for testing drugs or other therapies targeting at reducing inflammation through modulating POP2 expression and/or function, for testing drugs or other therapies targeting at modulating inflammation, influencing disease states, or preventing harmful side-effects where POP2 expression and/or function contributes to the biological process. As these mice are humanized (i.e. they express a protein that humans possess, but mice lack), they represent a potential resource for studies related to human inflammation without requiring human subjects, thus allowing a wider range of approaches.
The present application claims priority to U.S. Provisional Application No. 62/100,104, filed on Jan. 6, 2015.
This invention was made with government support under Grant No. R01A1072259 awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
62100104 | Jan 2015 | US |